The global Targeted Therapy Drugs market size is predicted to grow from US$ 153715 million in 2025 to US$ 224359 million in 2032; it is expected to grow at a CAGR of 5.8% from 2026 to 2032.

In 2025, global Targeted Therapy Drugs reached approximately 73.33 M Units, with an average global market price of around 2143 USD per Unit.

Targeted therapy drugs are medicines designed to specifically act on defined molecular targets?such as genes, proteins, receptors, or signaling pathways?that play a key role in the development or progression of a disease. Unlike traditional therapies that act broadly on rapidly dividing cells or whole organ systems, targeted therapies aim to interfere precisely with disease-driving mechanisms, thereby improving therapeutic effectiveness while reducing unintended damage to healthy cells.Targeted therapies are widely used in oncology, where they block cancer-specific mutations, growth signals, or angiogenesis pathways, but they are also increasingly important in autoimmune diseases, inflammatory disorders, and rare genetic conditions. These drugs may take the form of small molecules (often taken orally and acting inside cells) or biologics such as monoclonal antibodies (typically acting on extracellular or cell-surface targets). Their development relies heavily on advances in molecular biology, genomics, and biomarker identification.

Targeted therapy drugs address some of the most persistent pain points in modern medicine by moving beyond broad, non-specific treatment approaches toward therapies that act on clearly defined molecular drivers of disease, enabling better efficacy with a more manageable safety profile and greater consistency in patient response. By aligning treatment with genetic mutations, signaling pathways, or disease-specific receptors, these drugs help reduce unnecessary toxicity, avoid overtreatment, and improve outcomes in conditions where traditional therapies often fall short or show high variability. The expansion of genomic testing, biomarker discovery, and molecular diagnostics has accelerated the adoption of targeted therapies, while rising prevalence of cancer, autoimmune disorders, and rare diseases continues to fuel demand for more precise and durable treatment options. Looking ahead, the market potential for targeted therapy drugs remains strong as pipelines deepen across oncology and non-oncology indications, combination strategies improve resistance management, and healthcare systems increasingly recognize the long-term value of therapies that deliver predictable, mechanism-based benefits, positioning targeted therapies as a cornerstone of future drug development and precision medicine.

The upstream raw materials for Targeted Therapy Drugs mainly include active pharmaceutical ingredients (APIs), pharmaceutical intermediates, and excipients. Typical suppliers include Pfizer, Roche, Merck, and AstraZeneca, among others. Downstream applications are primarily in oncology and rare disease treatments.

The single-line production capacity of Targeted Therapy Drugs varies significantly depending on the drug molecule type, process complexity, equipment scale, and production mode. Industry gross margins typically range from 60% to 80%.

United States market for Targeted Therapy Drugs is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.

China market for Targeted Therapy Drugs is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.

Europe market for Targeted Therapy Drugs is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.

Global key Targeted Therapy Drugs players cover Roche, Novartis, Merck, Pfizer, AstraZeneca, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.

Infinity Market Research newest research report, the ?Targeted Therapy Drugs Industry Forecast? looks at past sales and reviews total world Targeted Therapy Drugs sales in 2025, providing a comprehensive analysis by region and market sector of projected Targeted Therapy Drugs sales for 2026 through 2032. With Targeted Therapy Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Targeted Therapy Drugs industry.

This Insight Report provides a comprehensive analysis of the global Targeted Therapy Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Targeted Therapy Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Targeted Therapy Drugs market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Targeted Therapy Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Targeted Therapy Drugs.

This report presents a comprehensive overview, market shares, and growth opportunities of Targeted Therapy Drugs market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

    Kinase Inhibitors
    ADC
    Others
    Segmentation by Administration Route:
    Oral Drugs
    Injectable Drugs
    Others
    Segmentation by Molecular Properties:
    Small Molecule Drugs
    Antibody Drugs
    Others

Segmentation by Application:

    Cancer
    Rare Diseases
    Others

This report also splits the market by region:

    Americas
        United States
        Canada
        Mexico
        Brazil
    APAC
        China
        Japan
        Korea
        Southeast Asia
        India
        Australia
    Europe
        Germany
        France
        UK
        Italy
        Russia
    Middle East & Africa
        Egypt
        South Africa
        Israel
        Turkey
        GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the companys coverage, product portfolio, its market penetration.

    Roche
    Novartis
    Merck
    Pfizer
    AstraZeneca
    Johnson & Johnson
    Bristol Myers Squibb
    Bayer
    GSK
    Daiichi Sankyo
    Amgen
    Eli Lilly and Company
    AbbVie
    Sanofi
    Takeda
    Boehringer Ingelheim
    Beigene, Ltd.
    Jiangsu Hengrui Medicine
    INNOVENT BIOLOGICS(SUZHOU)
    Betta Pharmaceuticals
    Remegen Co.,Ltd.
    Shanghai Allist Pharmaceuticals
    Innocare
    Huiyu Pharmaceuticals

Key Questions Addressed in this Report

What is the 10-year outlook for the global Targeted Therapy Drugs market?
What factors are driving Targeted Therapy Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Targeted Therapy Drugs market opportunities vary by end market size?
How does Targeted Therapy Drugs break out by Type, by Application?